Effect of Prednisolone Treatment on Uterine Natural Killer Cells
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Prednisolone.
- Who it may be relevant to
- Registry conditions: Recurrent Miscarriage. Basic parameters: 18 years — 40 years · Female.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Hong Kong
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Effect of Prednisolone Treatment on Uterine Natural Killer Cells and Endometrial Angiogenesis in Recurrent Miscarriage Around the Time of Embryo Implantation
Overview
This study aims to investigate the role of uNK cells and the association with prednisolone.
Detailed description
Glucocorticoids prednisolone is considered as a potential therapy in women with recurrent miscarriage. However, the evidence for treatment with prednisolone is still inconclusive and the relevant mechanism merits further investigations.
The participants will be invited to take prednisolone oral 10 mg/day and attend our outpaitent clinic to be performed endometrial biopsy.
Interventions
- Drug Prednisolone
prednisolone oral 10 mg/day from day one of the subsequent menstrual cycle to day LH 7 of that cycle. Then, the participants will be given a tailing off dose of 5 mg/day for 3 days followed by 2 mg/day for 3 days and then 1 mg/day for 3 days.
Primary outcome measures
- the number of uNK cells [Time frame: at the 1 day of endometrial biopsy]
Eligibility criteria
Inclusion criteria
- Women with a history of 3 or more consecutive miscarriages
- Women younger than 40 years old
Exclusion criteria
- Allergy to prednisolone
- Women who have any uterine anomaly
- Antiphospholipid syndrome
- Hydrosalpinx
- Thrombophilia
- Abnormal thyroid function tests
- women with diabetes,
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
Hong Kong · 1 center
- The Chinese University of Hong Kong — Hong Kong
Identifiers
NCT: NCT03902912 · 2018.586